PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma

被引:3
作者
Sahinli, Hayriye [1 ]
Akyurek, Nalan [2 ]
Yilmaz, Mukaddes [3 ]
Kandemir, Olcay [4 ]
Duran, Ayse Ocak [5 ]
Kulacoglu, Sezer [6 ]
Ucar, Gokhan [7 ]
Acar, Elif [2 ]
Ozet, Ahmet [3 ]
Gumus, Mahmut [8 ]
Oksuzoglu, O. Berna C. [5 ]
Ozdemir, Nuriye Y. [7 ]
机构
[1] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Oncol, Ankara, Turkey
[2] Gazi Univ, Dept Pathol, Med Hosp, Ankara, Turkey
[3] Gazi Univ, Dept Oncol, Med Univ Hosp, Ankara, Turkey
[4] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Dept Pathol, Ankara, Turkey
[5] Dr Abdurrahman Yurtaslan Ankara Oncol Hosp, Dept Oncol, Ankara, Turkey
[6] Ankara Numune Training & Res Hosp, Dept Pathol, Ankara, Turkey
[7] Ankara Numune Training & Res Hosp, Dept Oncol, Ankara, Turkey
[8] Istanbul Medipol Univ, Dept Oncol, Med Sch, Istanbul, Turkey
关键词
Nasopharyngeal carcinoma; prognosis; programmed death ligand-1; TUMOR-INFILTRATING LYMPHOCYTES; PROGRAMMED DEATH LIGAND-1; GASTRIC-CANCER; DISTINCT EXPRESSION; T-CELLS; MICROENVIRONMENT; CHEMORADIOTHERAPY; RADIOTHERAPY; SURVIVAL; PHASE;
D O I
10.4103/ijc.IJC_459_19
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Programmed death-ligand 1 (PD-L1) has been determined as a reliable prognostic factor for various malignancies. In this study, we aimed to determine the prognostic effect of PD-L1 expression in tumor-infiltrating immune cells (TIICs) of nasopharyngeal carcinoma (NPC) patients. Methods: Seventy patients diagnosed with non-metastatic NPC were included in the study. PD-L1 expression on immune cells was analyzed by immunohistochemical method. Patients were categorized into two groups according to the PD-L1 expression level in TIICs (level of PD-L1 staining >= 5% positive vs <5% negative). Results: Median follow-up period was 34 months (range = 1 - 188). 1 and 2 years survival rate were found as 75% and 63% in PD-L1 negative TIICs group (47%), and 85% and 83% in PD-L1 positive TIICs group (53%), respectively. PD-L1 positivity in immune cells (ICs) was detected in 53% of the patients. The survival rate was found better in the PD- L1 positive group compared to the negative group (P = 0.049). Discussion: In conclusion, the survival rate was found significantly better in the PD-L1 positive TIICs group, compared to the negative group.
引用
收藏
页码:561 / 566
页数:6
相关论文
共 50 条
  • [21] PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm
    Zheng, Kai-Fu
    Liu, Yu-Jian
    Ma, Nan
    Xiong, Yan-Lu
    Tang, Xi-Yang
    Zhang, Qian
    Luo, Zhong-Lin
    Tian, Huan-Huan
    Hofman, Paul
    Ichiki, Yoshinobu
    Metro, Giulio
    Tachihara, Motoko
    Gong, Li
    Li, Xiao-Fei
    Zhao, Jin-Bo
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4617 - +
  • [22] Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
    Lee, Lik Hang
    Cavalcanti, Marcela S.
    Sega, Neil H.
    Hechtman, Jaclyn F.
    Weiser, Martin R.
    Smith, J. Joshua
    Garcia-Aguilar, Julio
    Sadot, Eran
    Ntiamoah, Peter
    Markowitz, Arnold J.
    Shike, Moshe
    Stadler, Zsofia K.
    Vakiani, Efsevia
    Klimstra, David S.
    Shia, Jinru
    [J]. MODERN PATHOLOGY, 2016, 29 (11) : 1433 - 1442
  • [23] Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma
    Alessandrini, Lara
    Franz, Leonardo
    Ottaviano, Giancarlo
    Ghi, Maria Grazia
    Lanza, Cristiano
    Blandamura, Stella
    Marioni, Gino
    [J]. ORAL ONCOLOGY, 2020, 108
  • [24] Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
    Huang, Ta-Chen
    Liang, Cher-Wei
    Li, Yu-, I
    Guo, Jhe-Cyuan
    Lin, Chia-Chi
    Chen, Ya-Jhen
    Cheng, Ann-Lii
    Hsu, Chih-Hung
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (07) : 1803 - 1811
  • [25] PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial
    Cao, Caineng
    Wei, Qichun
    Tang, Xiuwen
    Jia, Yongshi
    Sun, Xiaonan
    Li, Wenfeng
    Hu, Qiaoying
    Chen, Xiaozhong
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (05): : 1427 - 1433
  • [26] Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma
    Jianwei Zhang
    Wenfeng Fang
    Tao Qin
    Yunpeng Yang
    Shaodong Hong
    Wenhua Liang
    Yuxiang Ma
    Hongyun Zhao
    Yan Huang
    Cong Xue
    Peiyu Huang
    Zhihuang Hu
    Yuanyuan Zhao
    Li Zhang
    [J]. Medical Oncology, 2015, 32
  • [27] PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma
    de Vicente, Juan C.
    Rodriguez-Santamarta, Tania
    Rodrigo, Juan P.
    Blanco-Lorenzo, Veronica
    Allonca, Eva
    Garcia-Pedrero, Juana M.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2019, 28 (03) : 546 - 554
  • [28] PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy
    Wakita, Akiyuki
    Motoyama, Satoru
    Nanjo, Hiroshi
    Sato, Yusuke
    Yoshino, Kei
    Sasaki, Tomohiko
    Kawakita, Yuta
    Liu, Jiajia
    Imai, Kazuhiro
    Saito, Hajime
    Minamiya, Yoshihiro
    [J]. ANTICANCER RESEARCH, 2017, 37 (03) : 1433 - 1441
  • [29] PD-1/PD-L1 as a prognostic factor in leukemia
    Rezaeeyan, Hadi
    Hassani, Seyedeh Nafiseh
    Barati, Mojgan
    Shahjahani, Mohammad
    Saki, Najmaldin
    [J]. JOURNAL OF HEMATOPATHOLOGY, 2017, 10 (01) : 17 - 24
  • [30] HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
    Jing, Chu-Yu
    Fu, Yi-Peng
    Yi, Yong
    Zhang, Mei-Xia
    Zheng, Su-Su
    Huang, Jin-Long
    Gan, Wei
    Xu, Xin
    Lin, Jia-Jia
    Zhang, Juan
    Qiu, Shuang-Jian
    Zhang, Bo-Heng
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7